Telix Pharmaceuticals Limited (TLX) has a MoatMap StockRank of 27/100 based on Quality (39/100), Value (22/100), and Momentum (53/100) factor scores. The current signal is SELL. Telix Pharmaceuticals is a rapidly growing leader in radiopharmaceuticals, a sector with an exceptionally high regulatory and manufacturing moat due to the short half-life of isotopes. Telix has established a highly secure, validated global supply chain and manufacturing network, giving it immense pricing power and structural advantages as the radiopharma market expands exponentially. Its commercialized imaging agent Illuccix provides robust cash flow to fund a deep therapeutic pipeline.
Telix Pharmaceuticals Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing diagnostic and therapeutic products using molecularly targeted radiation (MTR) for oncology. The company's lead product, Illuccix for prostate cancer imaging, provides a key competitive advantage in the rapidly growing field of theranostics. Telix is a notable player in radiopharmaceutical development, leveraging precision medicine to address critical cancer needs.
| Price | $9.41 |
| Market Cap | $3.2B |
| P/E (Forward) | 40.07 |
| Price/Book | 7.78 |
| Return on Equity | -1.9% |
| Return on Invested Capital | 3.8% |
| Debt/Equity | 112.45 |
| Gross Margin | 47.5% |
| Operating Margin | 1.9% |
| Revenue Growth | 49.3% |
| Free Cash Flow | $-37M |
Telix Pharmaceuticals Limited operates in the Biotechnology industry, part of the Healthcare sector (Australia).